Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer

Volumn 14, Issue 6, 2016, Pages 499-503

  Rini, Brian I ^a   Tomita, Yoshihiko ^b   Melichar, Bohuslav ^c   Ueda, Takeshi ^d   Grünwald, Viktor ^e   Fishman, Mayer N ^f   Uemura, Hirotsugu ^g   Oya, Mototsugu ^h   Bair, Angel H ⁱ   Andrews, Glen I ⁱ   Rosbrook, Brad ⁱ   Jonasch, Eric ^j  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^c PALACKÝ UNIVERSITY   (Czech Republic)

^d CHIBA CANCER CENTER   (Japan)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^g KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ PFIZER INC   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

First line treatment; Kidney cancer; mRCC; Phase II; VEGFR inhibitor

Indexed keywords

AXITINIB; EVEROLIMUS; ANGIOGENESIS INHIBITOR; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CAUSE OF DEATH; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DISEASE COURSE; DRUG DOSE TITRATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHONIA; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; PATIENT HISTORY OF NEPHRECTOMY; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; CARCINOMA, RENAL CELL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOUBLE BIND; DRUG ADMINISTRATION; KIDNEY NEOPLASMS; METASTASIS; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; DOUBLE BIND INTERACTION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMIDAZOLES; INDAZOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84969627266     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2016.04.005     Document Type: Article

References (11)

1. 1 Rugo, H.S., Herbst, R.S., Liu, G., et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 23 (2005), 5474–5483.
2. 2 Rini, B.I., Garrett, M., Poland, B., et al. Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol 53 (2013), 491–504.
3. 3 Rini, B.I., Melichar, B., Ueda, T., et al. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol 14 (2013), 1233–1242.
4. 4 Motzer, R.J., Escudier, B., McDermott, D.F., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 (2015), 1803–1813.
5. 5 Grunwald, V., McKay, R.R., Krajewski, K.M., et al. Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. Eur Urol 67 (2015), 952–958.
6. 6 Rini, B.I., Escudier, B., Hariharan, S., et al. Long-term safety with axitinib in previously treated patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 13 (2015), 540–547.
7. 7 Cohen, R.B., Oudard, S., Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities. Invest New Drugs 30 (2012), 2066–2079.
8. 8 Motzer, R.J., Nosov, D., Eisen, T., et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol 31 (2013), 3791–3799.
9. 9 Motzer, R.J., Hutson, T.E., Cella, D., et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369 (2013), 722–731.
10. 10 Motzer, R.J., Hutson, T.E., Tomczak, P., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27 (2009), 3584–3590.
11. 11 Sternberg, C.N., Hawkins, R.E., Wagstaff, J., et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 49 (2013), 1287–1296.